Evidence map›Paper›PMID 24454876›Full record

ArticlePloS one2014

RanBP9 overexpression accelerates loss of pre and postsynaptic proteins in the APΔE9 transgenic mouse brain.

Hongjie Wang, Ruizhi Wang, Shaohua Xu, Madepalli K Lakshmana

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hongjie WangSection of Neurobiology, Torrey Pines Institute for Molecular Studies, Port Saint Lucie, Florida, United States of America.
Ruizhi WangSection of Neurobiology, Torrey Pines Institute for Molecular Studies, Port Saint Lucie, Florida, United States of America.
Shaohua XuDepartment of Biological Sciences, Florida Institute of Technology, Melbourne, Florida, United States of America.
Madepalli K LakshmanaSection of Neurobiology, Torrey Pines Institute for Molecular Studies, Port Saint Lucie, Florida, United States of America.
Torrey Pines Institute For Molecular Studies · USFlorida Institute of Technology · US

Funding

Role of RanBP9 on dendritic and spine injury in an Alzheimer's mouse modelR01AG036859 · NIA · TORREY PINES INST FOR MOLECULAR STUDIES · PI LAKSHMANA, MADEPALLI KRISHNAPPA · 2010 to 2013
$1.1M
Effect of RanbpM on amyloid pathology in a mouse model of Alzheimer's diseaseR03AG032064 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LAKSHMANA, MADEPALLI KRISHNAPPA · 2008 to 2009
$131k
NIA NIH HHS 1R01AG036859-01NIA NIH HHS 1R03AG032064-01NIA NIH HHS R01 AG036859NIA NIH HHS R03 AG032064
6 · The paper itself

Abstract

There is now compelling evidence that the neurodegenerative process in Alzheimer's disease (AD) begins in synapses. Loss of synaptic proteins and functional synapses in the amyloid precursor protein (APP) transgenic mouse models of AD is well established. However, what is the earliest age at which such loss of synapses occurs, and whether known markers of AD progression accelerate functional deficits is completely unknown. We previously showed that RanBP9 overexpression leads to robustly increased amyloid β peptide (Aβ) generation leading to enhanced amyloid plaque burden in a mouse model of AD. In this study we compared synaptic protein levels among four genotypes of mice, i.e., RanBP9 single transgenic (Ran), APΔE9 double transgenic (Dbl), APΔE9/RanBP9 triple transgenic (Tpl) and wild-type (WT) controls. We found significant reductions in the levels of synaptic proteins in both cortex and hippocampus of 5- and 6-months-old but not 3- or 4-months-old mice. Specifically, at 5-months of age, rab3A was reduced in the triple transgenic mice only in the cortex by 25% (p<0.05) and gap43 levels were reduced only in the hippocampus by 44% (p<0.01) compared to wild-type (WT) controls. Interestingly, RanBP9 overexpression in the Tpl mice reduced gap43 levels by a further 31% (p<0.05) compared to APΔE9 mice. RanBP9 also further decreased the levels of drebrin in the hippocampus by 32% (p<0.01) and chromogranin in the cortex by 24% (p<0.05) compared to APΔE9 mice. At 6-months of age, RanBP9 expression in the cortex led to further reduction of rab3A by 30% (p<0.05) and drebrin by 38% (p<0.01) compared to APΔE9 mice. RanBP9 also increased Aβ oligomers in the cortex at 6 months. Similarly, in the hippocampus, RanBP9 expression further reduced rab3A levels by 36% (p<0.01) and drebrin levels by 33% (p<0.01). Taken together these data suggest that RanBP9 overexpression accelerates loss of synaptic proteins in the mouse brain.

Indexed as

Adaptor Proteins, Signal TransducingAmyloid beta-PeptidesAnimalsCerebral CortexChromogranin BGAP-43 ProteinGene ExpressionHippocampusHumansMaleMiceMice, TransgenicNeuropeptidesProtein MultimerizationProtein Structure, Secondaryrab3A GTP-Binding ProteinAdaptor Proteins, Signal TransducingAmyloid beta-PeptidesChromogranin BdrebrinsGAP-43 ProteinNeuropeptidesrab3A GTP-Binding Protein

Identifiers

PMID24454876
PMCPMC3891818
OpenAlexW2059545933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.